Liver transplantation in patients with hepatocellular carcinoma

Annals of Transplantation

Volumn 13, Issue 4, 2008, Pages 5-15

  Polak, Wojciech G ^a,b   Soyama, Akihiko ^a   Slooff, Maarten J H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Outcome; Percutaneous ethanol injection; Radio frequency ablation; Surgery; Transarterial chemoembolization

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; CALCINEURIN INHIBITOR; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; IODINATED POPPYSEED OIL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOXANTRONE; RAPAMYCIN; SORAFENIB;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; OVERALL SURVIVAL; PAIN; PERCUTANEOUS DRAINAGE; PERCUTANEOUS ETHANOL INJECTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RISK FACTOR; RISK REDUCTION; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT OUTCOME; TUMOR NECROSIS; EUROPE; HEPATITIS B; HEPATITIS C; LIVER TUMOR; PREVALENCE; REVIEW; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; EUROPE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PREVALENCE; UNITED STATES;

EID: 65849498440     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med, 2003; 139: 817-23
2. Bosch FX, Ribes J, Díaz M, Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology, 2004; 127(5 Suppl.1): S5-S16
3. Zaman SN, Melia WM, Johnson RD et al: Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet, 1985; 1: 1357-60
4. Brunati A, Feruzi Z, Sokal E et al: Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation. Pediatr Transplant, 2007; 11: 117-19
5. Kohno M, Kitatani H, Wada H et al: Hepatocellular carcinoma complicating biliary cirrhosis caused by biliary atresia: report of a case. J Pediatr Surg, 1995; 30: 1713-16
6. Fattovich G, Stroffolini T, Zagni I et al: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 2004; 127(5 Suppl.1): S35-50
7. Fasani P, Sangiovanni A, De Fazio et al: High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology, 1999; 29: 1704-7
8. Yuki K, Hirohashi S, Sakamoto M et al: Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer, 1990; 66: 2174-79
9. Okada S, Okazaki N, Nose H et al: Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology, 1992; 16: 112-17
10. Simonetti RG, Liberati A, Angiolini C, Pagliaro L: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol, 1997; 8: 117-36
11. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology, 2005; 42: 1208-36
12. Ringe B, Pichlmayr R, Wittekind C, Tusch G: Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg, 1991; 15: 270-85
13. Belghiti J, Panis Y, Farges O et al: Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg, 1991; 214: 114-17
14. Figueras J, Jaurrieta E, Valls C et al: Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology, 1997; 25: 1485-89
15. Lesurtel M, Müllhaupt B, Pestalozzi BC et al: Transarterial chemoembolization as a bridge to liver transplantation for epatocellular carcinoma: an evidence-based analysis. Am J Transplant, 2006; 6: 2644-50
16. Porrett PM, Peterman H, Rosen M et al: Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl, 2006; 12: 665-73
17. Liver transplantation. National Institutes of Health Consensus Development. Natl Inst Health Consens Dev Conf Summ, 1983; 4: 15
18. European Liver Transplant Registry. Data Analysis Booklet 05/1968-12/2003
19. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientifi c Registry of Transplant Recipients: Transplant Data 1997-2006. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; Arbor Research Collaborative for Health (formerly URREA), Ann Arbor, MI
20. O'Grady JG, Polson RJ, Rolles K et al: Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg, 1988; 207: 373-79
21. Ringe B, Wittekind C, Bechstein WO et al: The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg, 1989; 209: 88-98
22. Knight SR, Friend PJ, Morris PJ: Role of transplantation in the management of hepatic malignancy. Br J Surg, 2007; 94: 1319-30
23. Mazzaferro V, Regalia E, Doci R et al: Liver transplantationfor the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996; 334: 693-99
24. Yao FY, Ferrell L, Bass NM et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001; 33: 1394-403
25. Iwatsuki S, Starzl TE, Sheahan DG et al: Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg, 1991; 214: 221-28
26. Bismuth H, Chiche L, Adam R et al: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg, 1993; 218: 145-51
27. Lu DS, Yu NC, Raman SS, Lassman C et al: Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology, 2005; 41: 1130-37
28. Ojogho ON, So SK, Keeffe EB et al: Orthotopic liver transplantation for hepatocellular carcinoma. Factors affecting long-term patient survival. Arch Surg, 1996; 131: 935-39
29. Urahashi T, Lynch SV, Kim YH et al: Strong RW. Undetected hepatocellular carcinoma in patients undergoing liver transplantation: is associated with favorable outcome. Hepatogastroenterology, 2007; 54: 1192-95
30. Llovet JM, Bruix J, Gores GJ: Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology, 2000; 31: 1019-21
31. Cillo U, Vitale A, Grigoletto F et al: Intention-totreat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant, 2007; 7: 972-81
32. Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al: Impact of UCSF criteria according to preand post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl, 2006; 12: 1761-69
33. Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis, 2005; 25: 181-200
34. Hussain HK, Syed I, Nghiem HV et al: T2-weighted MR imaging in the assessment of cirrhotic liver. Radiology, 2004; 230: 637-44
35. Laghi A, Iannaccone R, Rossi P et al: Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology, 2003; 226: 543-49
36. Maluf DG, Stravitz RT, Williams B et al: Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience. Transplant Proc, 2007; 39: 153-59
37. Martin AP, Goldstein RM, Dempster J et al: Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation - a clinical and histological examination. Clin Transplant, 2006; 20: 695-705
38. Schwartz M, Roayaie S, Uva P: Treatment of HCC in patients awaiting liver transplantation. Am J Transplant, 2007; 7: 1875-81
39. Pawlik TM, Gleisner AL, Anders RA et al: Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg, 2007; 245: 435-42
40. Zavaglia C, De Carlis L, Alberti AB et al: Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol, 2005; 100: 2708-16
41. Jonas S, Bechstein WO, Steinmüller T et al: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology, 2001; 33: 1080-86
42. Klintmalm GB: Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg, 1998; 228: 479-90
43. Fiorentino M, Altimari A, Ravaioli M et al: Predictive value of biological markers for hepatocellular carcinoma patients reated with orthotopic liver transplantation. Clin Cancer Res, 2004; 10: 1789-95
44. Marsh JW, Finkelstein SD, Demetris AJ et al: Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl, 2003; 9: 664-71
45. Graziadei IW, Sandmueller H, Waldenberger P et al: Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl, 2003; 9: 557-63
46. Yao FY, Bass NM, Nikolai B et al: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl, 2002; 8: 873-83
47. Yao FY, Kinkhabwala M, LaBerge JM et al: The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant, 2005; 5(4 Pt 1): 795-804
48. Hu RH, Ho MC, Wu YM et al: Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin Transplant, 2005; 19: 175-80
49. Poon RT, Fan ST, Lo CM et al: Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg, 2002; 235: 373-82
50. Adam R, Azoulay D, Castaing D et al: Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg, 2003; 238: 508-18
51. Belghiti J, Cortes A, Abdalla EK et al: Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg, 2003; 238: 885-92
52. Majno PE, Sarasin FP, Mentha G, Hadengue A: Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology, 2000; 31(4): 899-906
53. Yamada R, Sato M, Kawabata M et al: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology, 1983; 148: 397-401
54. Roayaie S, Frischer JS, Emre SH et al: Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg, 2002; 235: 533-39
55. Hayashi PH, Ludkowski M, Forman LM et al: Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant, 2004; 4: 782-87
56. Maddala YK, Stadheim L, Andrews JC et al: Dropout rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl, 2004; 10: 449-55
57. Majno PE, Adam R, Bismuth H et al: Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg, 1997; 226: 688-701
58. Ravaioli M, Grazi GL, Ercolani G et al: Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation, 2004; 78: 1780-86
59. Liou TC, Shih SC, Kao CR et al: Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol, 1995; 23: 563-68
60. Harnois DM, Steers J, Andrews JC et al: Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg, 1999; 5: 192-99
61. Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al: Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl, 2005; 11: 767-75
62. Llovet JM, Real MI, Montana X et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002; 359: 1734-39
63. Poon RT, Ngan H, Lo CM et al: Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol, 2000; 73: 109-14
64. Sergio A, Cristofori C, Cardin R et al: Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol, 2008; 103:914-21
65. Livraghi T, Goldberg SN, Lazzaroni S et al: Small hepatocellular carcinoma: treatment with radio frequency ablation versus ethanol injection. Radiology, 1999; 210: 655-61
66. Livraghi T, Solbiati L, Meloni MF et al: Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology, 2003; 226: 441-51
67. Fontana RJ, Hamidullah H, Nghiem H et al: Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl, 2002; 8: 1165-74
68. Mazzaferro V, Battiston C, Perrone S et al: Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg, 2004; 240: 900-9
69. Pompili M, Mirante VG, Rondinara G et al: Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of effi cacy at explant analysis and of safety for tumor recurrence. Liver Transpl, 2005; 11: 1117-26
70. Fisher RA, Maluf D, Cotterell AH et al: Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant, 2004; 18: 502-12
71. Casaril A, Abu Hilal M, Harb A et al: The safety of radiofrequency thermal ablation in the treatment of liver malignancies. Eur J Surg Oncol, 2008; 34: 668-72
72. Chen TM, Huang PT, Lin LF, Tung JN: Major complications of ultrasound-guided percutaneous radiofrequency ablations for liver malignancies: single center experience. J Gastroenterol Hepatol, 2008; 23(8 Pt 2): e445-50
73. Eisele RM, Schumacher G, Jonas S, Neuhaus P: Radiofrequency ablation prior to liver transplantation: focus on complications and on a rare but severe case. Clin Transplant, 2008; 22: 20-28
74. Molmenti EP, Klintmalm GB: Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl, 2002; 8: 736-48
75. Chen MS, Li JQ, Zheng Y et al: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg, 2006; 243: 321-28
76. Livraghi T, Giorgio A, Marin G et al: Hepatocellular carcinoma and cirrhosis in 746 patients: longterm results of percutaneous ethanol injection. Radiology, 1995; 197: 101-8
77. Di Stasi M, Buscarini L, Livraghi T et al: Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol, 1997; 32: 1168-73
78. Ebara N, Ohto M, Sugiura N et al: Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. Gastroenterol Hepatol, 1990; 5: 616-26
79. Castroagudín JF, Delgado M, Villanueva A et al: Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc, 2005; 37: 3871-73
80. Wong LL, Tanaka K, Lau L, Komura S: Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant, 2004; 18: 227-34
81. Yao FY, Hirose R, LaBerge JM et al: A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl, 2005; 11: 1505-14
82. Freeman RB Jr, Steffick DE, Guidinger MK et al: Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant, 2008; 8(4 Pt 2): 958-76
83. Stone MJ, Klintmalm GB, Polter D et al: Neoadjuvant chemotherapy and liver ransplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology, 1993; 104: 196-202
84. Cherqui D, Piedbois P, Pierga JY et al: Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer, 1994; 73: 2721-26
85. Olthoff KM, Rosove MH, Shackleton CR et al: Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg, 1995; 221: 734-41
86. Abou-Alfa GK, Schwartz L, Ricci S et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 2006; 24: 4293-300.
87. Llovet JM, Ricci S, Mazzaferro V et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008; 359: 378-90
88. Richly H, Henning BF, Kupsch P et al: Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol, 2006; 17: 866-73
89. Guba M, von Breitenbuch P, Steinbauer M et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med, 2002; 8: 128-35
90. Kauffman HM, Cherikh WS, Cheng Y et al: Maintenance immunosuppression with target-ofrapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation, 2005; 80: 883-89
91. Toso C, Meeberg GA, Bigam DL et al: De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: longterm outcomes and side effects. Transplantation, 2007; 83: 1162-68